(VIANEWS) – Tidewater (TDW), Greenland Technologies Holding Corporation (GTEC), Eli Lilly and Company (LLY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Tidewater (TDW)
66.5% sales growth and 5.52% return on equity
Tidewater Inc., together with its subsidiaries, provides offshore support vessels and marine support services to the offshore energy industry through the operation of a fleet of marine service vessels worldwide. It provides services in support of offshore crude oil and natural gas exploration, field development, and production, as well as windfarm development and maintenance, including towing of and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workover, and production activities; offshore construction, and seismic and subsea support; geotechnical survey support for windfarm construction; and various specialized services, such as pipe and cable laying. The company operates anchor handling towing supply vessels, platform supply vessels, crew boats, utility vessels, and offshore tugs. The company serves oil and natural gas exploration, field development, and production companies; mid-sized and smaller independent exploration and production companies; foreign government-owned or government-controlled organizations, and other related companies; drilling contractors; and other companies, such as offshore construction, windfarm development, diving, and well stimulation companies. Tidewater Inc. was incorporated in 1956 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Tidewater has a trailing twelve months EPS of $1.06.
PE Ratio
Tidewater has a trailing twelve months price to earnings ratio of 62.18. Meaning, the purchaser of the share is investing $62.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.52%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 530% and 640%, respectively.
Yearly Top and Bottom Value
Tidewater’s stock is valued at $65.91 at 16:22 EST, below its 52-week high of $73.16 and way higher than its 52-week low of $20.02.
Volume
Today’s last reported volume for Tidewater is 446805 which is 49.57% below its average volume of 886096.
2. Greenland Technologies Holding Corporation (GTEC)
34.2% sales growth and 8.31% return on equity
Greenland Technologies Holding Corporation, through its subsidiaries, develops and manufactures transmission and drivetrain systems for material handling machineries and electric vehicles, and electric industrial vehicles in the People's Republic of China and internationally. The company offers transmission products for forklift trucks that are used in manufacturing and logistic applications, such as factories, workshops, warehouses, fulfillment centers, shipyards, and seaports. It also develops robotic cargo carriers. The company was founded in 2006 and is based in Hangzhou, the People's Republic of China.
Earnings Per Share
As for profitability, Greenland Technologies Holding Corporation has a trailing twelve months EPS of $0.23.
PE Ratio
Greenland Technologies Holding Corporation has a trailing twelve months price to earnings ratio of 16.3. Meaning, the purchaser of the share is investing $16.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.31%.
3. Eli Lilly and Company (LLY)
28.2% sales growth and 65.6% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $7.16.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 76.72. Meaning, the purchaser of the share is investing $76.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 65.6%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.1%, now sitting on 29.52B for the twelve trailing months.
4. Surgery Partners (SGRY)
6.5% sales growth and 3.08% return on equity
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Earnings Per Share
As for profitability, Surgery Partners has a trailing twelve months EPS of $-0.56.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.08%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Surgery Partners’s EBITDA is 2.5.
Sales Growth
Surgery Partners’s sales growth is 6% for the current quarter and 6.5% for the next.
